Now that everyone has taken a moment to breathe and maybe a couple of days off after a successful launch of the...
Read MoreElixir
Recent Posts
Inflammatory medications are one of the top drivers of specialty drug spend. While these costly drugs can provide...
Read MoreFrom continuing revolutionary advancements in gene therapy to the ongoing effects of the COVID-19 pandemic and the...
Read MoreThe member experience is key for Elixir. This means more than a simple letter or access to a member portal. We strive...
Read MoreAn End-of-Year Note from CEO Heyward Donigan
Read MoreWith rising drug costs, we’re all looking for ways to reduce out-of-pocket spend without sacrificing quality. Generic...
Read MorePrescription drug spend represented 13.7% of national health expenditures in 2018, totaling $500 billion, and is...
Read MoreThe 2021 audit cycle is coming to a close. The Centers for Medicare and Medicaid Services (CMS) issued its last...
Read MoreFrom development of a medication for treatment-resistant HIV with a novel mechanism of action to approval of Pfizer's...
Read More